Charles Bennett to Hematinics
This is a "connection" page, showing publications Charles Bennett has written about Hematinics.
Connection Strength
8.903
-
Improving oncology biosimilar launches in the EU, the USA, and Japan: an updated Policy Review from the Southern Network on Adverse Reactions. Lancet Oncol. 2020 12; 21(12):e575-e588.
Score: 0.676
-
End of an era of administering erythropoiesis stimulating agents among Veterans Administration cancer patients with chemotherapy-induced anemia. PLoS One. 2020; 15(6):e0234541.
Score: 0.656
-
End of an era for erythropoiesis-stimulating agents in oncology. Int J Cancer. 2020 05 15; 146(10):2829-2835.
Score: 0.641
-
Investigating Serious Adverse Drug Reactions in Patients Receiving Erythropoiesis-Stimulating Agents: A Root Cause Analysis Using the "ANTICIPATE" Framework. Am J Ther. 2018 Nov/Dec; 25(6):e670-e674.
Score: 0.585
-
Reply to A.M. Zeidan et al. J Clin Oncol. 2017 10 01; 35(28):3265.
Score: 0.537
-
Tale of Two Erythropoiesis-Stimulating Agents: Utilization, Dosing, Litigation, and Costs of Darbepoetin and Epoetin Among South Carolina Medicaid-Covered Patients With Cancer and Chemotherapy-Induced Anemia. J Oncol Pract. 2017 06; 13(6):e562-e573.
Score: 0.528
-
Effects of the US Food and Drug Administration Boxed Warning of Erythropoietin-Stimulating Agents on Utilization and Adverse Outcome. J Clin Oncol. 2017 Jun 10; 35(17):1945-1951.
Score: 0.526
-
Consensus on the Existence of Functional Erythropoietin Receptors on Cancer Cells. JAMA Oncol. 2016 Jan; 2(1):134-6.
Score: 0.481
-
Erythropoiesis-stimulating agents and quality of life: personal journeys of a cancer survivor, oncologist, and two cancer health services researchers. Br J Cancer. 2014 Jul 29; 111(3):421-3.
Score: 0.435
-
Anaphylaxis and hypotension after administration of peginesatide. N Engl J Med. 2014 May 22; 370(21):2055-6.
Score: 0.430
-
Emerging drugs for treatment of anemia of chronic kidney disease. Expert Opin Emerg Drugs. 2013 Dec; 18(4):421-9.
Score: 0.410
-
Forewarned is forearmed: erythropoietin use in CKD patients with cancer. J Nephrol. 2013 Sep-Oct; 26(5):805-6.
Score: 0.410
-
Association between pharmaceutical support and basic science research on erythropoiesis-stimulating agents. Arch Intern Med. 2010 Sep 13; 170(16):1490-8.
Score: 0.333
-
Reassessments of ESAs for cancer treatment in the US and Europe. Oncology (Williston Park). 2010 Mar; 24(3):260-8.
Score: 0.321
-
Intersecting guidelines: administering erythropoiesis-stimulating agents to chronic kidney disease patients with cancer. Semin Dial. 2009 Jan-Feb; 22(1):1-4.
Score: 0.294
-
Epoetin-associated pure red cell aplasia: past, present, and future considerations. Transfusion. 2008 Aug; 48(8):1754-62.
Score: 0.283
-
Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA. 2008 Feb 27; 299(8):914-24.
Score: 0.279
-
Does reimbursement affect physicians' decision making? Examples from the use of recombinant erythropoietin. Cancer Treat Res. 2008; 140:235-51.
Score: 0.276
-
Long-term outcome of individuals with pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant epoetin: a follow-up report from the Research on Adverse Drug Events and Reports (RADAR) Project. Blood. 2005 Nov 15; 106(10):3343-7.
Score: 0.234
-
Peginesatide for the treatment of anemia due to chronic kidney disease - an unfulfilled promise. Expert Opin Drug Saf. 2016 Oct; 15(10):1421-6.
Score: 0.126
-
American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. Blood. 2010 Nov 18; 116(20):4045-59.
Score: 0.084
-
American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. J Clin Oncol. 2010 Nov 20; 28(33):4996-5010.
Score: 0.084
-
Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update. Blood. 2008 Jan 01; 111(1):25-41.
Score: 0.068
-
Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update. J Clin Oncol. 2008 Jan 01; 26(1):132-49.
Score: 0.068
-
Recombinant human erythropoietin and overall survival in cancer patients: results of a comprehensive meta-analysis. J Natl Cancer Inst. 2005 Apr 06; 97(7):489-98.
Score: 0.057
-
Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. Blood. 2002 Oct 01; 100(7):2303-20.
Score: 0.048
-
Cancer- and chemotherapy-induced anemia. J Natl Compr Canc Netw. 2008 Jul; 6(6):536-64.
Score: 0.018
-
Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst. 2006 May 17; 98(10):708-14.
Score: 0.015